vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $142.2M, roughly 1.3× UNIVERSAL DISPLAY CORP \PA\). UNIVERSAL DISPLAY CORP \PA\ runs the higher net margin — 25.2% vs 13.3%, a 11.9% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -14.5%). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -5.3%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
AMPH vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $142.2M |
| Net Profit | $24.4M | $35.9M |
| Gross Margin | 46.8% | 74.6% |
| Operating Margin | 19.4% | 30.1% |
| Net Margin | 13.3% | 25.2% |
| Revenue YoY | -1.8% | -14.5% |
| Net Profit YoY | -35.7% | -44.3% |
| EPS (diluted) | $0.51 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $183.1M | $172.9M | ||
| Q3 25 | $191.8M | $139.6M | ||
| Q2 25 | $174.4M | $171.8M | ||
| Q1 25 | $170.5M | $166.3M | ||
| Q4 24 | $186.5M | $162.3M | ||
| Q3 24 | $191.2M | $161.6M | ||
| Q2 24 | $182.4M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | $24.4M | $66.3M | ||
| Q3 25 | $17.4M | $44.0M | ||
| Q2 25 | $31.0M | $67.3M | ||
| Q1 25 | $25.3M | $64.4M | ||
| Q4 24 | $38.0M | $46.0M | ||
| Q3 24 | $40.4M | $66.9M | ||
| Q2 24 | $37.9M | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | 46.8% | 76.1% | ||
| Q3 25 | 51.4% | 74.6% | ||
| Q2 25 | 49.6% | 77.2% | ||
| Q1 25 | 50.0% | 77.1% | ||
| Q4 24 | 46.5% | 77.0% | ||
| Q3 24 | 53.3% | 77.8% | ||
| Q2 24 | 52.2% | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 19.4% | 38.9% | ||
| Q3 25 | 13.2% | 30.9% | ||
| Q2 25 | 24.2% | 39.9% | ||
| Q1 25 | 21.9% | 41.9% | ||
| Q4 24 | 24.2% | 32.3% | ||
| Q3 24 | 29.8% | 41.5% | ||
| Q2 24 | 30.3% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | 13.3% | 38.4% | ||
| Q3 25 | 9.0% | 31.5% | ||
| Q2 25 | 17.8% | 39.2% | ||
| Q1 25 | 14.8% | 38.8% | ||
| Q4 24 | 20.4% | 28.4% | ||
| Q3 24 | 21.1% | 41.4% | ||
| Q2 24 | 20.8% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.51 | $1.40 | ||
| Q3 25 | $0.37 | $0.92 | ||
| Q2 25 | $0.64 | $1.41 | ||
| Q1 25 | $0.51 | $1.35 | ||
| Q4 24 | $0.74 | $0.96 | ||
| Q3 24 | $0.78 | $1.40 | ||
| Q2 24 | $0.73 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $516.4M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | — |
| Total Assets | $1.6B | $1.9B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $282.8M | $602.4M | ||
| Q3 25 | $276.2M | $603.0M | ||
| Q2 25 | $231.8M | $525.2M | ||
| Q1 25 | $236.9M | $571.3M | ||
| Q4 24 | $221.6M | $492.7M | ||
| Q3 24 | $250.5M | $551.6M | ||
| Q2 24 | $217.8M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $788.8M | $1.8B | ||
| Q3 25 | $776.7M | $1.7B | ||
| Q2 25 | $757.5M | $1.7B | ||
| Q1 25 | $751.3M | $1.7B | ||
| Q4 24 | $732.3M | $1.6B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.6B | $2.0B | ||
| Q3 25 | $1.7B | $1.9B | ||
| Q2 25 | $1.6B | $1.9B | ||
| Q1 25 | $1.6B | $1.9B | ||
| Q4 24 | $1.6B | $1.8B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.5B | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $108.9M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $32.9M | $31.1M | ||
| Q3 25 | $52.6M | $97.2M | ||
| Q2 25 | $35.6M | $51.9M | ||
| Q1 25 | $35.1M | $30.6M | ||
| Q4 24 | $29.0M | $34.7M | ||
| Q3 24 | $60.0M | $79.9M | ||
| Q2 24 | $69.1M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $15.1M | ||
| Q3 25 | $47.2M | $84.3M | ||
| Q2 25 | $25.0M | $37.5M | ||
| Q1 25 | $24.4M | $17.5M | ||
| Q4 24 | $16.6M | $22.0M | ||
| Q3 24 | $46.2M | $66.2M | ||
| Q2 24 | $63.1M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 8.7% | ||
| Q3 25 | 24.6% | 60.4% | ||
| Q2 25 | 14.3% | 21.8% | ||
| Q1 25 | 14.3% | 10.5% | ||
| Q4 24 | 8.9% | 13.6% | ||
| Q3 24 | 24.1% | 41.0% | ||
| Q2 24 | 34.6% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 9.3% | ||
| Q3 25 | 2.8% | 9.2% | ||
| Q2 25 | 6.1% | 8.4% | ||
| Q1 25 | 6.3% | 7.9% | ||
| Q4 24 | 6.7% | 7.8% | ||
| Q3 24 | 7.2% | 8.4% | ||
| Q2 24 | 3.3% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | 1.35× | 0.47× | ||
| Q3 25 | 3.03× | 2.21× | ||
| Q2 25 | 1.15× | 0.77× | ||
| Q1 25 | 1.39× | 0.47× | ||
| Q4 24 | 0.76× | 0.75× | ||
| Q3 24 | 1.48× | 1.19× | ||
| Q2 24 | 1.82× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
